Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Kura Oncology (KURA) Change in Receivables (2025 - 2026)

Kura Oncology has reported Change in Receivables over the past 2 years, most recently at $544000.0 for Q1 2026.

Quarterly Change in Receivables fell 98.83% to $544000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$39.4 million through Mar 2026, changed N/A year-over-year, with the annual reading at $6.7 million for FY2025, 227.38% up from the prior year.
Change in Receivables was $544000.0 for Q1 2026 at Kura Oncology, up from -$27.1 million in the prior quarter.
Over five years, Change in Receivables peaked at $46.7 million in Q1 2025 and troughed at -$44.2 million in Q2 2025.